|Bid||12.64 x 900|
|Ask||12.97 x 3100|
|Day's range||11.90 - 12.74|
|52-week range||6.18 - 27.96|
|Beta (5Y monthly)||0.47|
|PE ratio (TTM)||N/A|
|Earnings date||02 Nov 2022 - 07 Nov 2022|
|Forward dividend & yield||N/A (N/A)|
|1y target est||27.38|
Iovance Biotherapeutics (IOVA) reports a wider-than-expected second-quarter loss. The company is on track to initiate a rolling BLA submission for lifileucel in melanoma later this month.
Iovance (IOVA) is progressing well with the clinical development of its pipeline candidates. It expects to file a BLA with the FDA, seeking approval for its lead candidate to treat metastatic melanoma, this August.
As revealed by Securities and Exchange Commission filings dated Thursday, everyone who is anyone at Iovance, it seems, was hitting the buy button. Wayne Rothbaum, a member of the biotech company's board of directors and the president of healthcare sector investment fund Quogue Capital, disclosed two recent purchases of 500,000 shares of Iovance's common stock. Fellow board members Michael Weiser, Ryan Maynard, and Merrill McPeak also loaded up, with recent buys totaling a respective 10,000; 7,500; and 20,000 common shares.